NCT05190484View on ClinicalTrials.gov

bIosimilar of aDalimumab, an European evAluation

UnknownOBSERVATIONAL

Enrollment

1,050

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2024

Conditions

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisCrohn DiseaseUlcerative Colitis

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Fresenius Kabi

INDUSTRY

NCT05190484 - bIosimilar of aDalimumab, an European evAluation | Biotech Hunter | Biotech Hunter